The risk of hemorrhage among patients with warfarin-associated coagulopathy  by Garcia, D.A. et al.
ABSTRACTS
Gregory L. Moneta, MD, Abstracts Section Editor
Polymorphism in the 2-adernergic receptor and lipoprotein lipase
genes as risk determinants for idiopathic venous thromboembolism: A
multilocus, population-based prospective genetic analysis
Zee RY, Cook NR, Cheng S, et al. Circulation 2006;113:2193-200.
Conclusion: There are polymorphisms of the lipoprotein lipase genes
and the 2-adernergic receptor genes that appear to increase the risk of
venous thromboembolism.
Summary: Genes of coagulation, inflammation, and lipid metabolism
pathways are implicated in the risk of idiopathic venous thromboembolism
(VTE). The authors used DNA samples collected at baseline in the Physi-
cians Health Study. They genotyped 92 polymorphisms from 56 candidate
genes in 304 individuals in whom VTE developed (156 secondary and 144
idiopathic cases) and from 2070 individuals who remained free of vascular
disease. There was a mean follow-up of 13.2 years to determine whether
these polymorphisms contributed to the risk of VTE.
With respect to the occurrence idiopathic VTE, the factor V Leiden
mutation confirmed an odds ratio for VTE of 5.13 (95% confidence interval
[CI], 3.24-8.14; P  .0001), the N291S lipoprotein lipase gene polymor-
phism conferred an odds ratio of 3.09 (95% CI, 1.56 to 6.09; P .01), and
the Q27E 2-adernergic receptor gene polymorphism conferred an odds
ratio of 1.40 (95% CI, 1.09 to 1.79; P  .006).
Comment: Blood clots occur for a reason; and idiopathic VTE occurs
for a reason. I suspect that in addition to the major hypercoagulable
abnormalities that had been identified such as factor V Leiden and the
prothrombin gene mutation, there are going to be dozens of genetic
polymorphisms that alone or in combination with relatively mild clinical risk
factors for VTE result in an increased risk for VTE.
Pregnancy-associated plasma protein-A is markedly expressed by
monocyte-macrophage cells in vulnerable and ruptured carotid
atherosclerotic plaques: A link between inflammation and cerebro-
vascular events
Sangiorgi G, Mauriello A, Bonanno E, et al. J Am Coll of Cardiol 2006;47:
2201-11.
Conclusion:Histologic, experimental, and clinical studies have linked
atherosclerosis with inflammation. Unstable carotid plaques produce symp-
toms primarily by disruption and distal embolization. A number of biologic
markers may help identify unstable carotid plaques.
Summary: In this study, the authors investigated the role of pregnancy-
associated protein-A (PAPP-A) as a marker of potential carotid plaque
destabilization and rupture. After endarterectomy, carotid plaques and
serologic PAPP-A levels from 72 patients were analyzed. Indication for
endarterectomy was major stroke in 19 and transient ischemic attack in 24.
Twenty-nine patients were asymptomatic. As determined by histologic
examination, there were three plaque groups: group 1, stable plaques (n 
38); group 2, vulnerable plaques (n  13); and group 3, ruptured plaques
with thrombus (n  14). Plaques were examined for PAPP-A, smooth
muscle cells, T lymphocytes, and macrophages using immunohistochemical
(ICM) staining. Local PAPP-A production was assessed with polymerase
chain reaction (PCR), and double immunofluorescence microscopy was
used to characterize cell types expressing PAPP-A.
Serologic values of PAPP-A were group 1, 4.02 0.18 mIU/L; group
2, 7.43 0.97 mIU/L; and group 3, 6.97 0.75 mIU/L (1 vs 3, P .01;
1 vs 2, P  .004; 2 vs 3, P  .71, respectively). Expression of PAPP-A
showed mean scores of 0.62  0.06 for stable plaques of group 1, 2.54 
0.14 for vulnerable plaques of group 2, and 2.71  0.12 for ruptured
plaques (1 vs 2, P .001; 1 vs 3, P .001; 2 vs 3, P .37, respectively). In
groups 2 and 3, but not in group 1, PCR demonstrated local messenger
RNA PAPP-A production and double ICM confirmed monocyte/macro-
phage expression of PAPP-A.
Comment: It appears that PAPP-A is another potential marker of
carotid plaque destabilization. We are slowly moving towards identifying
which plaques are the most dangerous. What is truly needed, however, is the
identification of the asymptomatic plaques most likely to result in neurologic
symptoms. The next step should be to determine if PAPP-A values can
predict which initially asymptomatic plaques will eventually produce neuro-
logic symptoms.
Effects of statins on renal function after aortic cross clamping during
major vascular surgery
Schouten O, Kox NFM, Boersma E, et al. Am J Cardiol 2006;97:1383-85.
Conclusion: Statins may enhance preservation of renal function after
suprarenal aortic clamping.
Summary: Suprarenal aortic clamping can result in renal dysfunction.
This renal dysfunction is associated with increased postoperative morbidity
and mortality. In this study, the authors sought to evaluate the effects of
statins on renal function in patients undergoing suprarenal aortic cross-
clamping. From 1995 to 2005, the authors identified 77 patients with
normal preoperative renal function who required suprarenal aortic clamping
during a vascular surgical procedure. Of these, 28 patients were statin users.
Their mean age was 69  8 years, and 57 were men and 20 were women.
Creatinine levels were obtained before surgery and at days 1, 2, 3, 7, and 10
after surgery and compared between statin users and nonusers. An analysis of
variance model was used to provide adjustment for clamping time and blood
loss.
Before aortic cross-clamping, no differences were found in baseline
clinical characteristics or preoperative creatinine levels (0.93 vs 0.96mg/dL,
P  .59). There were also no differences in glomerular filtration rates
between the statin users and nonstatin users (79 vs 73 mL/min, P  0.1).
After vascular surgery with aortic cross-clamping above the renal arteries,
postoperative creatinine levels during the 30 days after surgery were
lower in statin users than in nonusers (analysis of variance P  .01, 1.17 vs
1.98 mg/dL). All patients that required postoperative hemodialysis were
nonstatin users (n  7, 9.1%).
Comment: It seems every month a new pleiotropic effect of statins is
discovered. Renal protective effects of statins have been demonstrated in
animal models and are thought to reflect the moderating influence of statins
on endothelial ischemic dysfunction and inflammation. Further work is
required to determine when statins must be initiated before aortic clamping
and what the optimal doses are to minimize ischemia-induced renal dysfunc-
tion.
The risk of hemorrhage among patients with warfarin-associated
coagulopathy
Garcia DA, Regan S, Crowther M, et al. J Am Coll Card 2006;47:804-8.
Conclusion: The 30-day risk of major bleeding is 1% in patients
treated with warfarin who develop an international normalized ratio (INR)
of between 5.0 and 9.0.
Summary: The authors sought to determine the risk of major bleeding
30 days in patients who were on warfarin therapy and who developed an
INR5.0. There were 101 centers that prospectively assembled a cohort of
6761 patients receiving warfarin. In this cohort, 1104 patients had a first
episode of INR 5.0, with 979 being eligible for the study. The primary
outcome variables were major hemorrhage (defined as fatal bleeding, bleed-
ing leading to hospitalization, bleeding requiring a transfusion of at least 2
units of packed red cells), or bleeding in a critical site such as intracranially or
in the retroperitoneum. All other bleeding episodes were considered minor.
Complete follow-up information was available in 976 (99.7%) of the eligible
patients.
Of the eligible patients, 937 (96%) had INR values between 5.0 and
9.0, with 80% of these patients having INR values 7.0. There was a 1.3%
(n  13) incidence of major hemorrhage during the 30-day follow-up
period. Patients whose INRwas between 5.0 and 9.0 had 0.96% incidence of
major bleeding. No fatal bleeding events occurred. Treatment for elevated
INR was withholding of warfarin in most patients, and only 8.7% treated
with vitamin K. Of the patients treated conservatively and retested on day 4
or 5, 50% then had an INR of 2.0.
Comment:Warfarin coagulopathy is common but easily treated in the
large majority of patients by simply withholding warfarin and rechecking the
INR in a few days. Conservative treatment is indicated in patients with
warfarin therapy who present with INRs that are elevated but9.0. Reduc-
tion in the INR to an acceptable level can be expected within a few days with
a minimal incidence of bleeding complications.
N-acetylcysteine and contrast-induced nephropathy in primary
angioplasty
Marenzi G, Assanelli E, Marana I, et al. New Engl J Med 2006;354:2773-82.
Conclusion: Oral and intravenous N-acetylcysteine may prevent
contrast-medium-induced nephropathy in patients treated with primary
coronary angioplasty for acute myocardial infarction.
Summary: The authors investigated N-acetylcysteine for prevention of
contrast-medium-induced nephropathy in patients undergoing coronary
angioplasty for acute myocardial infarction. This group of patients is char-
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